Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth

Inna Gertsenshteyn, Eugene Barth, Heejong Kim, Boris Epel, Lara Leoni, Hsiu-Ming Tsai, John Lukens, Subramanian Sundramoorthy, Mihai Giurcanu, Amandeep Ahluwalia, Xiaobing Fan, Erica Markiewicz, Marta Zamora, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Chien-Min Kao, Howard Halpern* and Chin-Tu Chen*
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 12;
Inna Gertsenshteyn
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Barth
2Radiation and Cellular Oncology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heejong Kim
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Epel
2Radiation and Cellular Oncology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lara Leoni
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsiu-Ming Tsai
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Lukens
2Radiation and Cellular Oncology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subramanian Sundramoorthy
2Radiation and Cellular Oncology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihai Giurcanu
3Public Health Sciences University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amandeep Ahluwalia
4University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaobing Fan
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica Markiewicz
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Zamora
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed Bhuiyan
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Freifelder
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Kucharski
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Min Kao
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard Halpern*
2Radiation and Cellular Oncology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-Tu Chen*
1Radiology University of Chicago Chicago IL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

12

Objectives: Tumor hypoxia is associated with resistance to therapy and tumor progression, and correlates negatively with patient survival [1, 2, 3]. 18F-Misonidazole (FMISO) is frequently used in clinical PET trials to measure and treat tumor hypoxia [4], but there is no universally accepted threshold to define tumor hypoxia with FMISO. This study uses electron paramagnetic resonance (EPR) pO2 images as true hypoxia (pO2 < 10 mmHg) [5] to calculate the optimal corresponding FMISO PET threshold for identifying hypoxic tumors in SCC7 tumor murine models of squamous cell carcinoma.

Methods: Imaging: Using SCC7 squamous cell carcinoma murine models (n=14), the tumor-bearing leg was immobilized in the plastic bed in a polysiloxane dental mold cast (GC America, Alsip, IL) with embedded fiducials to allow for co-registration between modalities. FMISO PET and EPR images were acquired in a hybrid PET/EPR system for simultaneous imaging [6], which gave the advantage of identical physiological conditions of the mouse. A tail-vein cannula was used to administer an oxygen-sensitive spin probe solution for EPR imaging. A bolus injection of ~230 uCi of FMISO (produced at the in-house cyclotron facility) was used for PET imaging; images were acquired 2-hours post-injection. T2-weighted images were acquired in a 9.4 Tesla small animal imager (Bruker, Erlangen, Germany) for registration and tumor/muscle contouring. Image analysis: Following MRI/EPR/PET registration in MATLAB, images were resampled to the PET image’s isotropic voxel resolution of [0.5 mm]3. The T2 MRI-based tumor and muscle contour were transformed to the PET and EPR images in units of tumor-to-muscle ratio (TMR) and pO2, respectively. Using a custom-written script in MATLAB, ROC curves were generated for each tumor across all thresholds of PET TMR > 0 to 5.6 in increments of 0.2, using EPR pO2 < 10 mmHg as true hypoxia. The accuracy (ACC) (fraction of true negatives and positives over all true/false negatives/positives), Dice Similarity Coefficient (DSC), and Hausdorff Distance (dH) were used to quantify overlap between hypoxic regions as defined by EPR and PET. Because maximum ACC and DSC are both between 0 and 1, with 1 corresponding to highest overlap, dH was normalized and subtracted from 1 (1 - || dH ||) so that the highest value would also show maximum overlap. The peak mean of ACC, DSC, and 1 - ||dH|| averaged over all tumors was used to determine the optimal PET threshold. The hypoxic fractions of tumor voxels based on resulting thresholds was also calculated to compare between modalities.

Results: For all tumors, the area under the ROC curve using pO2 < 10 mmHg as gold standard was AUC = 0.739 (SE = 0.03). The peak ACC = 0.816 (SE = 0.02) corresponding to the PET threshold TMR > 2.4, and peak DSC = 0.485 (SE = 0.05) corresponding to a threshold TMR 2.0. At its minimum, mean dH = 3.40 (SE = 0.2) mm at TMR > 2.4. The average value of ACC, DSC, and 1-|| dH || showed a peak at TMR > 2.2 and pO2 < 10 mmHg. The mean hypoxic fraction of EPR images was 0.20 (SE = 0.05), and of PET images was 0.19 (SE = 0.03), which was not significant based on the two-sample t-test (p = 0.51).

Conclusions: Based on this dataset of SCC7 squamous cell carcinoma murine models, the PET threshold of TMR > 2.2 has the highest ACC and DSC, and the lowest dH, when compared to hypoxic tumor regions defined by EPR pO2 < 10 mmHg. These results might help improve patient prognosis for more accurate hypoxia-based dose-painting treatment plans based on PET imaging. References: [1] Hockel, M et al. (1996). Cancer Res, 56(19): p. 4509-15.[2] Hockel, M and Vaupel, P (2001). J Natl Cancer Inst, 93(4): p. 266-76.[3] Brizel, DM et al. (1997). Int J Radiat Oncol Biol Phys, 38(2): p. 285-9.[4] Lopci, E et al. (2014). Am J Nucl Med Mol Imaging, 4: p. 365-384.[5] Epel, B et al. (2019). Int J Radiat Oncol Biol Phys, 103(4): p. 977-984.[6] Kim H et al. (2020). Nuclear Inst. and Methods in Physics Research Section, A, 959.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth
Inna Gertsenshteyn, Eugene Barth, Heejong Kim, Boris Epel, Lara Leoni, Hsiu-Ming Tsai, John Lukens, Subramanian Sundramoorthy, Mihai Giurcanu, Amandeep Ahluwalia, Xiaobing Fan, Erica Markiewicz, Marta Zamora, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Chien-Min Kao, Howard Halpern*, Chin-Tu Chen*
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 12;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth
Inna Gertsenshteyn, Eugene Barth, Heejong Kim, Boris Epel, Lara Leoni, Hsiu-Ming Tsai, John Lukens, Subramanian Sundramoorthy, Mihai Giurcanu, Amandeep Ahluwalia, Xiaobing Fan, Erica Markiewicz, Marta Zamora, Mohammed Bhuiyan, Richard Freifelder, Anna Kucharski, Chien-Min Kao, Howard Halpern*, Chin-Tu Chen*
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 12;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Human hippocampal [18F]nifene binding to nicotinic acetylcholinergic α4β2* receptors is reduced in postmortem Alzheimer’s disease brains
  • Evaluation of myocardial perfusion scintigraphy SPECT and CT images in patients with a history of COVID-19
  • Can absorbed radiation doses by organs and tumors after PRRT be estimated from a single SPECT/CT study?
Show more Oral - PhysicianPharm

CMIIT Young Investigator Award Session

  • Bispecific INV721 antibody improves specific targeting in neuroblastoma to limit neuropathic pain
  • Production of a Novel Fluorine-18 Labeled Silver Species Derived from [18F]HF
  • Synthesis and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2
Show more CMIIT Young Investigator Award Session

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire